← Back to Search

Genetic Testing

Genetic Testing for Prostate Cancer Screening (ProGRESS Trial)

N/A
Recruiting
Led By Jason L Vassy, MD MPH
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 years
Awards & highlights

ProGRESS Trial Summary

This trial will test if a genetic test can help identify which men are at highest risk for prostate cancer and who don't need biopsies. It could improve how male Veterans are screened for prostate cancer.

Who is the study for?
The ProGRESS study is for male Veterans aged 55-69 who regularly receive care from the VA. It's designed to help those at risk of prostate cancer and aims to reduce unnecessary biopsies in men with low risk by using genetic testing.Check my eligibility
What is being tested?
This trial tests a precision screening intervention based on genetic testing against usual care methods. The goal is to see if this new approach more accurately identifies men at high or low risk for significant prostate cancer.See study design
What are the potential side effects?
Since the intervention involves genetic testing rather than medication, traditional side effects are not applicable. However, there may be some psychological impact or anxiety associated with learning about one's genetic risk.

ProGRESS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Diagnosis of clinically significant prostate cancer
Negative prostate biopsy
Secondary outcome measures
Diagnosis of prostate cancer
PSA testing
Prostate MRI
+3 more
Other outcome measures
Acceptability of the precision prostate cancer screening intervention
Adherence to precision cancer screening recommendations
Rare pathogenic/likely pathogenic variants

ProGRESS Trial Design

2Treatment groups
Experimental Treatment
Group I: Usual careExperimental Treatment1 Intervention
Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
Group II: Precision screening interventionExperimental Treatment2 Interventions
The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,621 Previous Clinical Trials
3,318,501 Total Patients Enrolled
14 Trials studying Prostate Cancer
3,785 Patients Enrolled for Prostate Cancer
Jason L Vassy, MD MPHPrincipal InvestigatorVA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
2 Previous Clinical Trials
662 Total Patients Enrolled

Media Library

Precision screening intervention (Genetic Testing) Clinical Trial Eligibility Overview. Trial Name: NCT05926102 — N/A
Prostate Cancer Research Study Groups: Precision screening intervention, Usual care
Prostate Cancer Clinical Trial 2023: Precision screening intervention Highlights & Side Effects. Trial Name: NCT05926102 — N/A
Precision screening intervention (Genetic Testing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05926102 — N/A
~3333 spots leftby Sep 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top